mRNA therapeutics company Ethris GmbH announced on Monday the appointment of Thomas Langenickel, MD as its new chief medical officer.
Most recently, Dr Langenickel has served as executive director and head of Respiratory Profiling within the Translational Medicine Group at Novartis AG.
Previously, Dr Langenickel has held positions of increasing responsibility in Discovery Medicine at Bristol Myers Squibb.
Dr Langenickel will guide the company's first drug candidate ETH42 into development as well as support further activities to build a pipeline of transcript therapies for pulmonary disorders, commented CMO Thomas Langenickel. It is developing a portfolio of SNIM RNA therapies for genetic respiratory ciliopathies as well as researching SNIM RNA therapies for treatment of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis exclusively with AstraZeneca.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review